Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

Talaris Therapeutics logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Advanced Chart

Key Stats

Today's Range
$15.93
$17.04
50-Day Range
$12.36
$28.36
52-Week Range
$0.89
$27.95
Volume
297,227 shs
Average Volume
386,531 shs
Market Capitalization
$713.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TALS Stock News Headlines

Tourmaline Bio, Inc. (TRML)
Trump Makes Major Crypto Announcement
Pay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design.
Longitude Venture Partners III, L.P.'s Net Worth
See More Headlines

TALS Stock Analysis - Frequently Asked Questions

Talaris Therapeutics, Inc. (NASDAQ:TALS) announced its earnings results on Friday, November, 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03.

Talaris Therapeutics (TALS) raised $150 million in an IPO on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Talaris Therapeutics investors own include Graphite Bio (GRPH), Vaccitech (VACC), Achilles Therapeutics (ACHL), Allogene Therapeutics (ALLO), Cytec Industries (CYT), Immunocore (IMCR) and Century Therapeutics (IPSC).

Company Calendar

Last Earnings
11/12/2021
Today
5/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TALS
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.89 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.33 per share
Price / Book
3.85

Miscellaneous

Free Float
35,708,000
Market Cap
$713.30 million
Optionable
Not Optionable
Beta
2.18
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:TALS) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners